Critical Survey: China SXT Pharmaceuticals (NASDAQ:SXTC) vs. PMV Pharmaceuticals (NASDAQ:PMVP)

China SXT Pharmaceuticals (NASDAQ:SXTC) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Risk & Volatility

China SXT Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares China SXT Pharmaceuticals and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Institutional & Insider Ownership

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares China SXT Pharmaceuticals and PMV Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14 million	82.14	-$6.20 million	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.90

China SXT Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings for China SXT Pharmaceuticals and PMV Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1	0	0	0	1.00
PMV Pharmaceuticals	1	0	2	1	2.75

PMV Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 198.51%. Given PMV Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Summary

PMV Pharmaceuticals beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.